Wessex severe asthma cohort
Lead Research Organisation:
University of Southampton
Department Name: Inflammation Infection and Repair
Abstract
Asthma is a common and disabling problem for many, particularly those with severe persistent disease that prevents them living a normal life. Standard asthma therapies are insufficient to control symptoms in these individuals and they live in fear of exacerbations that require emergency care and hospitalisation. There is thus an urgent need for the identification of novel therapeutic approaches that improve disease control and prevent disease exacerbation. To enable the more rapid conduct of trials with potential new treatments it is important to have well characterised patients, as it is recognised that severe asthma may arise from a range of causes and not all individuals are likely to benefit in the same way with specific interventions. With this in mind, this proposal will gather patients within the Wessex region with severe asthma, to form a Wessex severe asthma cohort, that can undergo detailed characterisation and be available to potentially take parts in trials of new therapies. This characterisation will involve documenting the impact of the disease on daily symptoms and quality of life, focusing on the presence and severity of nasal and sinus symptoms. Measures will be made of how well the lungs are working through a series of breathing tests. Biological samples, such as sputum, collected by inducing coughing, nasal washings, blood and urine will be collected and used to assess the nature, extent and severity of asthmatic inflammation within the airways and body. It is intended that the cohort would act as a focus for the evaluation of novel treatments that are being developed in the hope that they would lead to improvement in asthma in those with more severe disease. The characterisation would help determine which patients might best be selected for different interventions, dependent upon how these work, to give the best chance of identifying better treatments that can be developed to help improve the quality of life in those with severe asthma.
Technical Summary
This cohort of patients with persistent and severe asthma specifically responds to a significant unmet clinical need and is not duplicated within National Service Framework strategies or any Topic Specific Clinical Research Networks, as none exist for asthma. This will provide well characterised subjects that facilitate the proof of principle investigation of novel therapies with a sound rationale in this group of patients. The collection and characterisation of these patients reflects a strong partnership between NHS and academic respiratory physicians in Wessex and the close geographic localisation makes possible the potential conduct of sophisticated, mechanistic, translational, pharmacological studies that would not be possible in a widely disseminated cohort and for which Southampton has a proven track record.
Three hundred patients with asthma who, despite regular maintenance therapy at level 4 or level 5 of the British Thoracic Society asthma management guidelines, remain symptomatic and have unstable disease, in that they have a history of severe exacerbation necessitating a course of oral steroids or an increased in maintenance oral steroid dose, will be recruited. Characterisation, in addition to a detailed history which will include details of smoking habit and medication use, will consist of 1) patient centered questionnaires and diary card recording of upper and lower airway symptoms, to evaluate the impact of the disease on the individual, 2) physiological measures of lung function at home and in the laboratory before and after bronchodilator therapy, to assess lung function in relationship to the norm (predicted values), the natural diurnal variation and the short term pharmacological reversibility of any impairment, 3) biological sample collection to evaluate airway inflammation within the upper and lower airways and to store samples from induced sputum, nasal lavage, peripheral blood (serum and plasma) and urine for subsequent biomarker evaluation, for which separate funding would need to be applied for. Additional assessments include documentation of atopic status, measurement of BMI and measurement of urinary cotinine to verify tobacco smoking history.
A range of potential mechanistic proof of principle studies on novel therapies that could be undertaken on this cohort of patients with severe asthma are detailed, along with possible industrial collaborators. These focus on modifying the effect or exposure to trigger factors (viruses and bacteria), the underlying abnormal airway inflammation (eosinophilic and neutrophilic) or specific disease processes through molecular targeting.
Three hundred patients with asthma who, despite regular maintenance therapy at level 4 or level 5 of the British Thoracic Society asthma management guidelines, remain symptomatic and have unstable disease, in that they have a history of severe exacerbation necessitating a course of oral steroids or an increased in maintenance oral steroid dose, will be recruited. Characterisation, in addition to a detailed history which will include details of smoking habit and medication use, will consist of 1) patient centered questionnaires and diary card recording of upper and lower airway symptoms, to evaluate the impact of the disease on the individual, 2) physiological measures of lung function at home and in the laboratory before and after bronchodilator therapy, to assess lung function in relationship to the norm (predicted values), the natural diurnal variation and the short term pharmacological reversibility of any impairment, 3) biological sample collection to evaluate airway inflammation within the upper and lower airways and to store samples from induced sputum, nasal lavage, peripheral blood (serum and plasma) and urine for subsequent biomarker evaluation, for which separate funding would need to be applied for. Additional assessments include documentation of atopic status, measurement of BMI and measurement of urinary cotinine to verify tobacco smoking history.
A range of potential mechanistic proof of principle studies on novel therapies that could be undertaken on this cohort of patients with severe asthma are detailed, along with possible industrial collaborators. These focus on modifying the effect or exposure to trigger factors (viruses and bacteria), the underlying abnormal airway inflammation (eosinophilic and neutrophilic) or specific disease processes through molecular targeting.
Organisations
- University of Southampton, United Kingdom (Lead Research Organisation)
- Fraunhofer Society (Collaboration)
- University College London, United Kingdom (Collaboration)
- Shino-Test Corporation (Collaboration)
- Catholic University of the Sacred Heart (Collaboration)
- Jagiellonian University, Poland (Collaboration)
- University of Catania, Italy (Collaboration)
- Newcastle University, United Kingdom (Collaboration)
- Boehringer Ingelheim, Germany (Collaboration)
- University of Bern (Collaboration)
- Academic Medical Center (Collaboration)
- Hvidovre Hospital (Collaboration)
- Novartis (Collaboration)
- University of Ghent, Belgium (Collaboration)
- University of Nottingham (Collaboration)
- University of Oxford, United Kingdom (Collaboration)
- National Institute for Health Research, United Kingdom (Collaboration)
- Karolinska Institute, Sweden (Collaboration)
- Imperial College London, United Kingdom (Collaboration)
- Queen's University of Belfast, United Kingdom (Collaboration)
- Royal Brompton & Harefield NHS Foundation Trust (Collaboration)
- Aix-Marseille University, France (Collaboration)
- University of Rome II (Tor Vergata), Italy (Collaboration)
- National Institutes of Health, United States (Collaboration)
- Umea University, Sweden (Collaboration)
- University of Copenhagen, Denmark (Collaboration)
- Semmelweis University (Collaboration)
- National Center for Scientific Research (Centre National de la Recherche Scientifique CNRS) (Collaboration)
- Haukeland University Hospital (Collaboration)
- University of Manchester, Manchester, United Kingdom (Collaboration)
- King's College London, United Kingdom (Collaboration)
- University of Leicester, United Kingdom (Collaboration)
Publications
Azim A
(2021)
Peripheral airways type 2 inflammation, neutrophilia and microbial dysbiosis in severe asthma.
in Allergy
Bachert C
(2012)
Specific IgE against Staphylococcus aureus enterotoxins: an independent risk factor for asthma.
in The Journal of allergy and clinical immunology
Bel EH
(2014)
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
in The New England journal of medicine
Blume C
(2013)
Barrier responses of human bronchial epithelial cells to grass pollen exposure.
in The European respiratory journal
Brown T
(2018)
Randomised controlled trials in severe asthma: selection by phenotype or stereotype.
in The European respiratory journal
Davies ER
(2016)
Soluble ADAM33 initiates airway remodeling to promote susceptibility for allergic asthma in early life.
in JCI insight
Francisco-Garcia AS
(2019)
Small RNA Species and microRNA Profiles are Altered in Severe Asthma Nanovesicles from Broncho Alveolar Lavage and Associate with Impaired Lung Function and Inflammation.
in Non-coding RNA
Gangwar RS
(2017)
CD48 on blood leukocytes and in serum of asthma patients varies with severity.
in Allergy
Grainge C
(2013)
Case series reporting the effectiveness of mycophenolate mofetil in treatment-resistant asthma.
in The European respiratory journal
Grainge C
(2014)
Asthmatic and normal respiratory epithelial cells respond differently to mechanical apical stress.
in American journal of respiratory and critical care medicine
| Description | NHS Severe Asthma Commissioning |
| Geographic Reach | National |
| Policy Influence Type | Participation in a national consultation |
| Impact | Establishment of specialist commissioned centres for severe asthma delivery and only centres for initiation of biologics for severe asthma. Restricted focus allows more standardisation and optimisation of health care delivery |
| Description | local asthma guidelines |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Membership of a guideline committee |
| Description | 12/33 HTA CET Open Call |
| Amount | £1,247,983 (GBP) |
| Funding ID | PROJECT: 12/33/28 |
| Organisation | National Institute for Health Research |
| Department | Health Technology Assessment Programme (HTA) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2014 |
| End | 02/2018 |
| Description | IMI ENSO-3 award |
| Amount | € 894,416 (EUR) |
| Funding ID | Grant Agreement No 115010 |
| Organisation | European Commission |
| Department | Seventh Framework Programme (FP7) |
| Sector | Public |
| Country | European Union (EU) |
| Start | 05/2014 |
| End | 10/2015 |
| Description | Innovate Medicines Innitiative/European Union/ European Federation of Pharmaceutical Industries |
| Amount | £479,407 (GBP) |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 10/2010 |
| End | 10/2015 |
| Description | Stratified Medicine |
| Amount | £5,951,787 (GBP) |
| Funding ID | MR/M016579/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2015 |
| End | 04/2019 |
| Description | Stratified Medicine Pilot projects |
| Amount | £25 (GBP) |
| Organisation | National Institute for Health Research |
| Department | MRC-NIHR National Phenome Centre |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 04/2016 |
| End | 10/2016 |
| Description | AirProm |
| Organisation | University of Leicester |
| Department | Institute for Lung Health |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Partner in application to EU FP7 for Airway Disease PRedicting Outcomes through Patient Specific Computational Modelling (AirPROM). Contributing CT thorax scans from well characterised severe asthma patients |
| Impact | None to date just started |
| Start Year | 2010 |
| Description | Airway microbiome and severe asthma |
| Organisation | University of Oxford |
| Department | Nuffield Department of Clinical Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Collection of biological samples from patients involved in the Wessex Severe Asthma Cohort alongside their detailed Clinico-physiological and biological characterisation |
| Collaborator Contribution | Link with Dr Tim Hinks in Department of Respiratory Medicine for Oxford Nanopore analysis of samples from Wessex severe asthma cohort |
| Impact | No outputs yet |
| Start Year | 2019 |
| Description | Asthma UK Genetics of Severe Asthma (AUGOSA) |
| Organisation | University of Nottingham |
| Department | School of Biomedical Sciences Nottingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Contributing DNA from Wessex Severe Asthma Cohort for genome wide screen to define genetics of severe asthma |
| Impact | (1)Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, von Mutius E, Farrall M, Lathrop M, Cookson WO; GABRIEL Consortium. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med. 2010 Sep 23;363(13):1211-21. |
| Start Year | 2009 |
| Description | Etosis and Netosis analysis in severe asthma |
| Organisation | Newcastle University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Research collaboration to provide sputum supernatant samples from WSAC study for etosis and netosis assay |
| Collaborator Contribution | Collaboration with Professor James Chalmers who has established etosis and netosis assays to investigate anti-bacterial responses within the airways linked to eosinophilic and neutrophilic airway inflammation |
| Impact | No output yet |
| Start Year | 2020 |
| Description | GWAS and severe asthma |
| Organisation | National Institutes of Health (NIH) |
| Department | Severe Asthma Research Programme |
| Country | United States |
| Sector | Public |
| PI Contribution | The Wessex Severe Asthma Cohort (WSAC)characterisation included the collection of a sample for DNA analysis. There was no funding for this. Partners have been sought to enable this to happen. |
| Collaborator Contribution | Collaboration has been set up with the US Severe Asthma Research Programme (SARP) and their centre for genetic analysis (Wake Forest University with Professors Eugen Bleecker and Debbie Meyers) to undertake a GWAS analysis similar to that conducted on the SARP population. This would serve as validatory data for SARP and novel data for WSAC. Novartis have funded the GWAS analysis through purchase of all the kits and reagents necessary for this to be undertaken. Payment has thus been in kind. Analysis will be in 2014 and interpretation in 2015. |
| Impact | not yet |
| Start Year | 2013 |
| Description | GWAS and severe asthma |
| Organisation | Novartis |
| Country | Global |
| Sector | Private |
| PI Contribution | The Wessex Severe Asthma Cohort (WSAC)characterisation included the collection of a sample for DNA analysis. There was no funding for this. Partners have been sought to enable this to happen. |
| Collaborator Contribution | Collaboration has been set up with the US Severe Asthma Research Programme (SARP) and their centre for genetic analysis (Wake Forest University with Professors Eugen Bleecker and Debbie Meyers) to undertake a GWAS analysis similar to that conducted on the SARP population. This would serve as validatory data for SARP and novel data for WSAC. Novartis have funded the GWAS analysis through purchase of all the kits and reagents necessary for this to be undertaken. Payment has thus been in kind. Analysis will be in 2014 and interpretation in 2015. |
| Impact | not yet |
| Start Year | 2013 |
| Description | Longitudinal follow up study of Wessex Severe Asthma Cohort |
| Organisation | Boehringer Ingelheim |
| Country | Germany |
| Sector | Private |
| PI Contribution | PI led study (Professor Peter Howarth) in collaboration with Boehringer Ingelheim to provide follow up data on those participants of the Wessex Severe Asthma Cohort who had sputum and inflammatory mediator measures as part of their initial assessment, to understand phenotype stability and evaluate the relationship between change in inflammation and change in disease control in severe asthma. |
| Collaborator Contribution | Boehringer Ingelheim will fund the clinical study and sample collection. Further funding will help support the sample analysis, the details of which have yet to be determined and will be undertaken in partnership. |
| Impact | None as yet as just started |
| Start Year | 2017 |
| Description | O-link protein analysis of sputum supernatant samples, venous blood and nasal lavage in severe asthma |
| Organisation | Boehringer Ingelheim |
| Country | Germany |
| Sector | Private |
| PI Contribution | Clinical, physiological and biological characterisation of patients with severe asthma and comparator mild/moderate asthma and healthy controls, along with provision of biological samples |
| Collaborator Contribution | Funding of O-link protein assays in Sweden for biological samples |
| Impact | No outputs yet |
| Start Year | 2019 |
| Description | Respiratory Therapeutic Capability Cluster |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Actively involved in the establishment and application process to secure TCC status for Respiratory Medicine. The npresence of airways disease cohorts was a requirement for consideration for participation in this Capability Cluster so the Wessex Severe Asthma cohort was an important factor in Southampton's inclusion. |
| Impact | Only recently formed so no output as yet. Respiratory with focus on asthma and COPD. Links with ABPI and large Pharma. |
| Start Year | 2010 |
| Description | Respiratory Therapeutic Capability Cluster |
| Organisation | National Institute for Health Research |
| Department | NIHR Biomedical Research Unit, Nottingham University Hospitals NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Actively involved in the establishment and application process to secure TCC status for Respiratory Medicine. The npresence of airways disease cohorts was a requirement for consideration for participation in this Capability Cluster so the Wessex Severe Asthma cohort was an important factor in Southampton's inclusion. |
| Impact | Only recently formed so no output as yet. Respiratory with focus on asthma and COPD. Links with ABPI and large Pharma. |
| Start Year | 2010 |
| Description | Respiratory Therapeutic Capability Cluster |
| Organisation | Queen's University Belfast |
| Department | Centre for Infection and Immunity |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Actively involved in the establishment and application process to secure TCC status for Respiratory Medicine. The npresence of airways disease cohorts was a requirement for consideration for participation in this Capability Cluster so the Wessex Severe Asthma cohort was an important factor in Southampton's inclusion. |
| Impact | Only recently formed so no output as yet. Respiratory with focus on asthma and COPD. Links with ABPI and large Pharma. |
| Start Year | 2010 |
| Description | Respiratory Therapeutic Capability Cluster |
| Organisation | Royal Brompton & Harefield NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Actively involved in the establishment and application process to secure TCC status for Respiratory Medicine. The npresence of airways disease cohorts was a requirement for consideration for participation in this Capability Cluster so the Wessex Severe Asthma cohort was an important factor in Southampton's inclusion. |
| Impact | Only recently formed so no output as yet. Respiratory with focus on asthma and COPD. Links with ABPI and large Pharma. |
| Start Year | 2010 |
| Description | Respiratory Therapeutic Capability Cluster |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Actively involved in the establishment and application process to secure TCC status for Respiratory Medicine. The npresence of airways disease cohorts was a requirement for consideration for participation in this Capability Cluster so the Wessex Severe Asthma cohort was an important factor in Southampton's inclusion. |
| Impact | Only recently formed so no output as yet. Respiratory with focus on asthma and COPD. Links with ABPI and large Pharma. |
| Start Year | 2010 |
| Description | Respiratory Therapeutic Capability Cluster |
| Organisation | University of Leicester |
| Department | Institute for Lung Health |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Actively involved in the establishment and application process to secure TCC status for Respiratory Medicine. The npresence of airways disease cohorts was a requirement for consideration for participation in this Capability Cluster so the Wessex Severe Asthma cohort was an important factor in Southampton's inclusion. |
| Impact | Only recently formed so no output as yet. Respiratory with focus on asthma and COPD. Links with ABPI and large Pharma. |
| Start Year | 2010 |
| Description | Respiratory Therapeutic Capability Cluster |
| Organisation | University of Manchester |
| Department | School of Medicine Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Actively involved in the establishment and application process to secure TCC status for Respiratory Medicine. The npresence of airways disease cohorts was a requirement for consideration for participation in this Capability Cluster so the Wessex Severe Asthma cohort was an important factor in Southampton's inclusion. |
| Impact | Only recently formed so no output as yet. Respiratory with focus on asthma and COPD. Links with ABPI and large Pharma. |
| Start Year | 2010 |
| Description | Respiratory Therapeutic Capability Cluster |
| Organisation | University of Oxford |
| Department | Oxford Centre for Respiratory Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Actively involved in the establishment and application process to secure TCC status for Respiratory Medicine. The npresence of airways disease cohorts was a requirement for consideration for participation in this Capability Cluster so the Wessex Severe Asthma cohort was an important factor in Southampton's inclusion. |
| Impact | Only recently formed so no output as yet. Respiratory with focus on asthma and COPD. Links with ABPI and large Pharma. |
| Start Year | 2010 |
| Description | U-BIOPRED |
| Organisation | Academic Medical Center |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | The existance of the "Wessex severe asthma cohort" was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners. |
| Collaborator Contribution | Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application |
| Impact | IMI severe asthma funding from EU/EFPIA for the consortium of €23 million Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest. 2010 Jun;137(6):1410-6 |
| Start Year | 2009 |
| Description | U-BIOPRED |
| Organisation | Aix-Marseille University |
| Country | France |
| Sector | Academic/University |
| PI Contribution | The existance of the "Wessex severe asthma cohort" was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners. |
| Collaborator Contribution | Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application |
| Impact | IMI severe asthma funding from EU/EFPIA for the consortium of €23 million Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest. 2010 Jun;137(6):1410-6 |
| Start Year | 2009 |
| Description | U-BIOPRED |
| Organisation | Catholic University of the Sacred Heart |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | The existance of the "Wessex severe asthma cohort" was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners. |
| Collaborator Contribution | Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application |
| Impact | IMI severe asthma funding from EU/EFPIA for the consortium of €23 million Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest. 2010 Jun;137(6):1410-6 |
| Start Year | 2009 |
| Description | U-BIOPRED |
| Organisation | Fraunhofer Society |
| Country | Germany |
| Sector | Private |
| PI Contribution | The existance of the "Wessex severe asthma cohort" was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners. |
| Collaborator Contribution | Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application |
| Impact | IMI severe asthma funding from EU/EFPIA for the consortium of €23 million Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest. 2010 Jun;137(6):1410-6 |
| Start Year | 2009 |
| Description | U-BIOPRED |
| Organisation | Haukeland University Hospital |
| Country | Norway |
| Sector | Hospitals |
| PI Contribution | The existance of the "Wessex severe asthma cohort" was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners. |
| Collaborator Contribution | Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application |
| Impact | IMI severe asthma funding from EU/EFPIA for the consortium of €23 million Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest. 2010 Jun;137(6):1410-6 |
| Start Year | 2009 |
| Description | U-BIOPRED |
| Organisation | Hvidovre Hospital |
| Country | Denmark |
| Sector | Hospitals |
| PI Contribution | The existance of the "Wessex severe asthma cohort" was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners. |
| Collaborator Contribution | Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application |
| Impact | IMI severe asthma funding from EU/EFPIA for the consortium of €23 million Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest. 2010 Jun;137(6):1410-6 |
| Start Year | 2009 |
| Description | U-BIOPRED |
| Organisation | Imperial College London |
| Department | National Heart & Lung Institute (NHLI) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The existance of the "Wessex severe asthma cohort" was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners. |
| Collaborator Contribution | Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application |
| Impact | IMI severe asthma funding from EU/EFPIA for the consortium of €23 million Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest. 2010 Jun;137(6):1410-6 |
| Start Year | 2009 |
| Description | U-BIOPRED |
| Organisation | Jagiellonian University |
| Department | Jagiellonian University Medical College |
| Country | Poland |
| Sector | Academic/University |
| PI Contribution | The existance of the "Wessex severe asthma cohort" was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners. |
| Collaborator Contribution | Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application |
| Impact | IMI severe asthma funding from EU/EFPIA for the consortium of €23 million Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest. 2010 Jun;137(6):1410-6 |
| Start Year | 2009 |
| Description | U-BIOPRED |
| Organisation | Karolinska Institute |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | The existance of the "Wessex severe asthma cohort" was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners. |
| Collaborator Contribution | Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application |
| Impact | IMI severe asthma funding from EU/EFPIA for the consortium of €23 million Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest. 2010 Jun;137(6):1410-6 |
| Start Year | 2009 |
| Description | U-BIOPRED |
| Organisation | National Center for Scientific Research (Centre National de la Recherche Scientifique CNRS) |
| Country | France |
| Sector | Academic/University |
| PI Contribution | The existance of the "Wessex severe asthma cohort" was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners. |
| Collaborator Contribution | Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application |
| Impact | IMI severe asthma funding from EU/EFPIA for the consortium of €23 million Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest. 2010 Jun;137(6):1410-6 |
| Start Year | 2009 |
| Description | U-BIOPRED |
| Organisation | Semmelweiss University |
| Country | Hungary |
| Sector | Academic/University |
| PI Contribution | The existance of the "Wessex severe asthma cohort" was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners. |
| Collaborator Contribution | Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application |
| Impact | IMI severe asthma funding from EU/EFPIA for the consortium of €23 million Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest. 2010 Jun;137(6):1410-6 |
| Start Year | 2009 |
| Description | U-BIOPRED |
| Organisation | Umea University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | The existance of the "Wessex severe asthma cohort" was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners. |
| Collaborator Contribution | Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application |
| Impact | IMI severe asthma funding from EU/EFPIA for the consortium of €23 million Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest. 2010 Jun;137(6):1410-6 |
| Start Year | 2009 |
| Description | U-BIOPRED |
| Organisation | University of Bern |
| Country | Switzerland |
| Sector | Academic/University |
| PI Contribution | The existance of the "Wessex severe asthma cohort" was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners. |
| Collaborator Contribution | Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application |
| Impact | IMI severe asthma funding from EU/EFPIA for the consortium of €23 million Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest. 2010 Jun;137(6):1410-6 |
| Start Year | 2009 |
| Description | U-BIOPRED |
| Organisation | University of Catania |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | The existance of the "Wessex severe asthma cohort" was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners. |
| Collaborator Contribution | Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application |
| Impact | IMI severe asthma funding from EU/EFPIA for the consortium of €23 million Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest. 2010 Jun;137(6):1410-6 |
| Start Year | 2009 |
| Description | U-BIOPRED |
| Organisation | University of Copenhagen |
| Country | Denmark |
| Sector | Academic/University |
| PI Contribution | The existance of the "Wessex severe asthma cohort" was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners. |
| Collaborator Contribution | Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application |
| Impact | IMI severe asthma funding from EU/EFPIA for the consortium of €23 million Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest. 2010 Jun;137(6):1410-6 |
| Start Year | 2009 |
| Description | U-BIOPRED |
| Organisation | University of Ghent |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | The existance of the "Wessex severe asthma cohort" was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners. |
| Collaborator Contribution | Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application |
| Impact | IMI severe asthma funding from EU/EFPIA for the consortium of €23 million Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest. 2010 Jun;137(6):1410-6 |
| Start Year | 2009 |
| Description | U-BIOPRED |
| Organisation | University of Manchester |
| Department | School of Medicine Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The existance of the "Wessex severe asthma cohort" was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners. |
| Collaborator Contribution | Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application |
| Impact | IMI severe asthma funding from EU/EFPIA for the consortium of €23 million Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest. 2010 Jun;137(6):1410-6 |
| Start Year | 2009 |
| Description | U-BIOPRED |
| Organisation | University of Nottingham |
| Department | School of Molecular Medical Sciences Nottingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The existance of the "Wessex severe asthma cohort" was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners. |
| Collaborator Contribution | Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application |
| Impact | IMI severe asthma funding from EU/EFPIA for the consortium of €23 million Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest. 2010 Jun;137(6):1410-6 |
| Start Year | 2009 |
| Description | U-BIOPRED |
| Organisation | University of Rome Tor Vergata |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | The existance of the "Wessex severe asthma cohort" was an key component in Southampton's involvement and credibilty within this European Union and EFPIA funded IMI grant. Southampton is one of the three leading centres co-ordinating this pan-European consortium that involves 20 academic institutes, patient organisations, SMEs and industrial partners. |
| Collaborator Contribution | Co-applicant on the IMI severe asthma U-BIOPRED application Co-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationCo-applicant on the IMI severe asthma U-BIOPRED applicationLead applicant on the IMI severe asthma grant application |
| Impact | IMI severe asthma funding from EU/EFPIA for the consortium of €23 million Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest. 2010 Jun;137(6):1410-6 |
| Start Year | 2009 |
| Description | serum periostin as a T2 biomarker in severe asthma |
| Organisation | Shino-Test Corporation |
| Country | Japan |
| Sector | Private |
| PI Contribution | Wessex Severe asthma cohort serum samples |
| Collaborator Contribution | measurement of serum periostin |
| Impact | European Respiratory Society poster presentation Munich 2014 Serum periostin in asthma: A potential biomarker for stratification in severe treatment-resistant asthma H. Rupani, L. Lau, J. Ono, S. Ohta, C. Barber, S. Elliot, T. Brown, R. Kurukulaaratchy, A. Chauhan, K. Izuhara, P. Howarth (Southampton, Portsmouth, United Kingdom; Kanagawa, Saga, Japan) |
| Start Year | 2013 |
| Title | University of Southampton for MicroRNA Treatment for Asthma (11413 / BB Ref. JDM68318P.USP) |
| Description | Multiple targeting of microRNAs as a therapy for asthma Scientific Summary: Multiple targeting of microRNAs as a therapy for asthma and Inflammatory Bowel Disease. The idea is based on the results that we have obtained in our laboratory, where we have observed a dysregulation in the expression of several microRNAs, both in Asthma and Inflammatory Bowel Disease (IBD). We did not stop at this descriptive fact, but studied the implications of this dysregulation, focusing on different microRNAs in different cells types and processes. This approach has facilitated the discovery of synergies or collaborations between multiple microRNAs. We have found that multiple microRNAs may be used simultaneously as therapeutic targets, eliciting a more controlled response that individual microRNAs. Our initial experiments have shown that microRNAs that have a specific target mRNA (of therapeutic interest) in common tend to increase their affinity for this target when they are simultaneously manipulated in the cell. Having an increased preference for the common therapeutic target, these microRNAs seem to show less avidity for other targets of no therapeutic interest, reducing the potential off target effects of a potential microRNA therapy. Alveolar macrophages from asthmatics were found to significantly over express a range of miRs, including miR27, miR150, miR152, miR155 and miR375. All of these have seeding sites within the 3'UTRs of genes that lie within host defence pathways which may have a role in asthmatic exacerbation due to rhinoviral infection. MiR-150, miR-152 and miR-375, which were significantly increased in severe asthma (SA), putatively regulate TLR7 expression. Consistent with this we found TLR-7 mRNA and protein (Western blotting) to be significantly reduced in AM from volunteers with SA compared to HC (p<0.003). This was identified as functionally relevant, as AM from SA exhibited deficient interferon-beta (IFN-ß? responses to stimulation with both Imiquimod (TLR7 agonist) and HRV16 in comparison to those from HC (each p<0.05). Importantly we were able to reverse this defect using an anti-microRNA oligonucleotide mix that blocked miR-150, miR-152 and miR-375, indicative of the relevance of these miRs. This innate recognition defect will be compounded, as MiR-27, miR-152 and miR155 are predicted to target Ripk1 (which inhibits TNF-a secretion). Consistent with this we found that transfection with a mix of oligonucleotide mimics for these 3 miRs enhanced the gene expression of TNF-a in alveolar macrophages after their exposure to HRV16. Additional results also suggest the relevance of miRs to altered AM bacterial recognition in asthma. In epithelial cells from asthmatics we have found that several microRNAs are significantly downregulated (miR-18, miR19, miR-27a, miR-128 and miR-155). All of these microRNAs target the TGF-b pathway in epithelium (targeting SMAD2 and the receptor for TGF-b), an important pro-remodelling factor thought to be key in asthma pathogenesis. MicroRNA reduction in asthmatic epithelial cells increases their sensitivity to asthma, favouring expression of pro-fibrotic genes and facilitating rhinoviral replication. In samples from patients suffering of IBD we found that miR-31 and miR-155 were upregulated and that both microRNAs target IL13RA1, the mRNA for the receptor of IL13, a key cytokine in IBD. By using both pre-miR-31 and pre-miR-155 oligonucleotides simultaneously on clinical biopsies from inflamed colon, we were able to show that genes dependent on IL13 stimulation were reduced (CCL18, SOCS1). Importantly, using the pre-miR-155 oligonucleotide alone increased TNF-?, an undesired and dangerous off target effect. However, when miR-155 was combined with pre-miR-31 this effect disappeared and only the common effects (reduction of IL13 dependent genes) were apparent and further increased. We claim that, by using multiple microRNA therapy, specific to pathology related signalling pathways and to the affected cells (epithelium, macrophages, etc) we enhance the effect of a potential microRNA therapy an can reduce its off target effect. |
| IP Reference | GB1316651.7 |
| Protection | Patent application published |
| Year Protection Granted | 2014 |
| Licensed | No |
| Impact | Work on going |
| Title | Temperature-controlled Laminar airflow (TLA) device |
| Description | Trial of a temperature-controlled laminar airflow device for the provision of clean filtered air to breathe at night in those with severe allergic asthma |
| Type | Therapeutic Intervention - Medical Devices |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2018 |
| Development Status | On hold |
| Clinical Trial? | Yes |
| Impact | negative trial . No impact on disease exacerbation report in HEALTH TECHNOLOGY ASSESSMENT VOLUME 23 ISSUE 29 June 2019 ISSN 1366-5278 |
| URL | https://clinicaltrials.gov/show/NCT02813811 |
| Description | Advisory board severe asthma |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Pharmaceutical company advisory board re drug development in severe asthma help develop direction of drug development |
| Year(s) Of Engagement Activity | 2012,2013,2014 |
| Description | Advisory board severe asthma |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Advisory board concerning drug development in severe asthma |
| Year(s) Of Engagement Activity | 2015 |
| Description | Conference on Clincal and Pharmacological aspects of asthma management |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | lecture on "Pharmacological modulation of airway remodelling in asthma" highlighting the preventative strategies in asthma therapy to prevent long term decline in lung function and how this influences everyday practice in asthma management |
| Year(s) Of Engagement Activity | 2016 |
| Description | EU grant review re severe asthma |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | International |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | IMI JU Interim Review Meeting for U-BIOPRED (project no 115010). Presentation as WP leader. successful approval of grant progress |
| Year(s) Of Engagement Activity | 2012 |
| Description | European Academy of Allergy, Asthma and Clinical Immunology Conference presentation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | International |
| Primary Audience | Other academic audiences (collaborators, peers etc.) |
| Results and Impact | Presentation on "The Airway Microbiome and Asthma" at pleneray symposium on Wednesday 26 June Presentation entitled "Pathology of the small airways in asthma" at the joint World Allergy Organisation and EAAACI symposium on Monday, 24 June 2013 Involvement in World Allergy Organisation publication on Small Airways and Asthma |
| Year(s) Of Engagement Activity | 2013 |
| Description | Newspaper article |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Article in local Southampton Echo newspaper about severe asthma needs and also a second outlining research activity in Southampton general awareness of asthma |
| Year(s) Of Engagement Activity | 2012 |
| Description | Wessex Asthma Network meeting |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | presentation on "How can phenotyping guide our management? " to primary care physicians, secondary care specialists, physiotherapists, specialist nurses, specialist commissioners, psychologists and patient representatives. Part of network meeting to promote asthma care and delivery of specialist services within the Wessex Region. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Workshop severe asthma |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Workshop considering how to diagnose severe asthma and approaches to severe asthma management, complemented by clinical cases and group discussions |
| Year(s) Of Engagement Activity | 2015 |
| Description | World Allergy Organisation conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Several presentations at International conference relating to aspects of severe asthma. Titles "Asthma therapy based on phenotypes and response to ICS of eosinophilic and non-eosinophilic type", "Impact of Environmental Factors on Modulating Epithelial Cell Function in Asthma" and "IL-17 and Th17 Cells in Asthma and Inflammation". These all included data derived from the Wessex Severe Asthma Cohort. Interactions with Korean workers interested in severe asthma. |
| Year(s) Of Engagement Activity | 2015 |
| Description | World Asthma Congress |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | lecture on "Non-Inflammatory mechanisms of airway remodelling" highlighting the importance of addressing bronchoconstriction as well as airway inflammation in management of asthma |
| Year(s) Of Engagement Activity | 2016 |
| Description | preceptorship severe asthma meeting |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | organisation and conduct of a one day workshop on severe asthma for respiratory specialists |
| Year(s) Of Engagement Activity | 2015 |
| Description | talk for Netherlands Lung Foundation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | talk and workshop for Netherlands Lung Foundation on "Current treatment of asthma and current medical needs" to help in their decision process re forward planning for funding strategy appreciation of the help given |
| Year(s) Of Engagement Activity | 2014 |